CN108368006B - 具有小沟结合尾部的dna结合剂 - Google Patents

具有小沟结合尾部的dna结合剂 Download PDF

Info

Publication number
CN108368006B
CN108368006B CN201680066385.9A CN201680066385A CN108368006B CN 108368006 B CN108368006 B CN 108368006B CN 201680066385 A CN201680066385 A CN 201680066385A CN 108368006 B CN108368006 B CN 108368006B
Authority
CN
China
Prior art keywords
compound
group
hydrogen
methyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680066385.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368006A (zh
Inventor
瓦尔德马·伯莱比
郭利伟
阿卡迪斯·卡奇梅尔斯基
伊莎贝拉·福克
查尔斯·康拉德
蒂莫西·梅登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN108368006A publication Critical patent/CN108368006A/zh
Application granted granted Critical
Publication of CN108368006B publication Critical patent/CN108368006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/62—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings
    • C07C13/66—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/244—Anthraquinone radicals, e.g. sennosides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201680066385.9A 2015-09-16 2016-09-16 具有小沟结合尾部的dna结合剂 Active CN108368006B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219380P 2015-09-16 2015-09-16
US62/219,380 2015-09-16
PCT/US2016/052144 WO2017049091A1 (en) 2015-09-16 2016-09-16 Dna binding agents with a minor groove binding tail

Publications (2)

Publication Number Publication Date
CN108368006A CN108368006A (zh) 2018-08-03
CN108368006B true CN108368006B (zh) 2023-03-07

Family

ID=58289623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680066385.9A Active CN108368006B (zh) 2015-09-16 2016-09-16 具有小沟结合尾部的dna结合剂

Country Status (8)

Country Link
US (1) US10358439B2 (enExample)
EP (1) EP3350145B1 (enExample)
JP (1) JP6966428B2 (enExample)
CN (1) CN108368006B (enExample)
AU (1) AU2016323777B2 (enExample)
CA (1) CA2998867A1 (enExample)
PL (1) PL3350145T3 (enExample)
WO (1) WO2017049091A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4433039A4 (en) * 2021-11-17 2025-10-29 Univ Texas WATER-SOLUBLE SALTS OF DNA-BINDING AGENTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196127A (en) * 1978-06-01 1980-04-01 Research Corporation Anthracyclines
US4591636A (en) * 1980-07-18 1986-05-27 Hoffmann-La Roche Inc. Anthracycline glycosides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288608A (en) * 1978-06-01 1981-09-08 Research Corporation Synthesis of anthracyclines
ZA814722B (en) * 1980-07-18 1982-07-28 Hoffmann La Roche Novel anthracycline glycosides
EP0971716A1 (en) * 1996-03-22 2000-01-19 Waldemar Priebe Bis-anthracyclines with high activity against doxorubicin resistant tumors
GB9812937D0 (en) * 1998-06-16 1998-08-12 Btg Int Ltd Compounds
WO2000056267A2 (en) 1999-03-19 2000-09-28 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
WO2003072058A2 (en) 2002-02-27 2003-09-04 The Government Of The United States Of America, Representated By The Secretary, Deparment Of Health And Human Services Dna-binding polyamide drug conjugates
KR101186210B1 (ko) * 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
SE0401066D0 (sv) * 2004-04-22 2004-04-22 Stefan Sjoeberg Chemical Derivatives
PL380561A1 (pl) 2006-09-05 2008-03-17 Szeja Wiesław Prochem Szeja Sposób otrzymywania pochodnych antracyklin
JP2012520298A (ja) * 2009-03-12 2012-09-06 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Ｇａｂａに結合したアントラサイクリン−脂質複合体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196127A (en) * 1978-06-01 1980-04-01 Research Corporation Anthracyclines
US4591636A (en) * 1980-07-18 1986-05-27 Hoffmann-La Roche Inc. Anthracycline glycosides

Also Published As

Publication number Publication date
AU2016323777B2 (en) 2021-05-13
CN108368006A (zh) 2018-08-03
US10358439B2 (en) 2019-07-23
PL3350145T3 (pl) 2021-05-04
WO2017049091A1 (en) 2017-03-23
JP2018527372A (ja) 2018-09-20
CA2998867A1 (en) 2017-03-23
US20180251454A1 (en) 2018-09-06
EP3350145A4 (en) 2019-03-27
EP3350145A1 (en) 2018-07-25
JP6966428B2 (ja) 2021-11-17
AU2016323777A1 (en) 2018-04-12
EP3350145B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
AU2023226641A1 (en) Compositions for the delivery of trna as nanoparticles and methods of use therewith
JP6890097B2 (ja) リンパ腫を処置するためのｅｚｈ２阻害剤
JP6474404B2 (ja) ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
CN103958502B (zh) 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
JP2021506797A (ja) Ｈｓｐ９０標的化コンジュゲート及びその製剤
WO2024140597A1 (zh) Wrn解旋酶抑制剂
JP4162994B2 (ja) 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
JP2013525419A (ja) 抗増殖性障害の処置における使用のためのｐｉ３ｋ阻害剤としてのピペラジノトリアジン
CN108368006B (zh) 具有小沟结合尾部的dna结合剂
AU2018246138A1 (en) Compositions and method of treating cancer
CN107072970A (zh) 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
HK1259495A1 (en) Dna binding agents with a minor groove binding tail
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
HK1259495B (en) Dna binding agents with a minor groove binding tail
WO2018067551A1 (en) Texaphyrin and antitumor antibiotic conjugates
JP2024521824A (ja) マクロライド化合物
US20250009727A1 (en) Water-soluble salts of dna binding agents
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
JP7789725B2 (ja) ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法
CN110981803B (zh) 一种抗肿瘤化合物及其合成方法与应用
CN116802175A (zh) 新型谷氨酰胺类似物
CN118359640A (zh) Prmt5-mta抑制剂
TW202128707A (zh) 稠合四環類衍生物、其製備方法及其在醫藥上的應用
KR20200085815A (ko) 과증식성 질병의 치료를 위한 카페인산 유도체
HK1190069A (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259495

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant